Drive Therapeutics of Research Triangle Park received $100,000 to develop a novel nucleic acid therapy to block angiogenesis, inflammation and fibrosis underlying retinal disease. Drive will use the loan funds to optimize and characterize lead-candidate aptamers to treat wet age-related macular degeneration and diabetic macular edema retinal diseases.
See the rest of the press release here.